| pubmed-article:69489 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:69489 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:69489 | lifeskim:mentions | umls-concept:C0002211 | lld:lifeskim |
| pubmed-article:69489 | lifeskim:mentions | umls-concept:C0301896 | lld:lifeskim |
| pubmed-article:69489 | lifeskim:mentions | umls-concept:C0030956 | lld:lifeskim |
| pubmed-article:69489 | lifeskim:mentions | umls-concept:C0301625 | lld:lifeskim |
| pubmed-article:69489 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:69489 | pubmed:dateCreated | 1977-9-29 | lld:pubmed |
| pubmed-article:69489 | pubmed:abstractText | The suppression of tumor-specific cell-mediated cytotoxicity by human immunoregulatory alpha-globulin (IRA), by a peptide fraction derived from IRA, and by IRA-like peptides from the serum of cancer patients was studied in a syngeneic murine tumor-host system. Splenic lymphocytes from tumor-immunized mice were cytotoxic specific tumor cells in vitro as measured by the [125]-iododeoxyuridine release microcytotoxicity assay. However, this effect was significantly depressed if 1.25 to 5 mg of IRA per ml were added to the cultures. Pooled lyophilized normal human serum protein was inactive. IRA peptide and IRA-like peptide fractions from cancer patients were also highly suppressive of cell-mediated cytotoxicity at much lower concentrations (0.05 to 0.5 mg/ml). Control human serum peptide, which failed to inhibit the induction of hemolytic plaque-forming cells in sheep erythrocyte-injected mice, had no effect on cell-mediated cytotoxicity. IRA and IRA-like peptide fractions were not cytotoxic to the effector lymphocytes or to the target cells at the concentrations used. | lld:pubmed |
| pubmed-article:69489 | pubmed:language | eng | lld:pubmed |
| pubmed-article:69489 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:69489 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:69489 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:69489 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:69489 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:69489 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:69489 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:69489 | pubmed:issn | 0008-5472 | lld:pubmed |
| pubmed-article:69489 | pubmed:author | pubmed-author:SchmidKK | lld:pubmed |
| pubmed-article:69489 | pubmed:author | pubmed-author:MannickJ AJA | lld:pubmed |
| pubmed-article:69489 | pubmed:author | pubmed-author:WaldA SAS | lld:pubmed |
| pubmed-article:69489 | pubmed:author | pubmed-author:CooperbandS... | lld:pubmed |
| pubmed-article:69489 | pubmed:author | pubmed-author:BadgerA MAM | lld:pubmed |
| pubmed-article:69489 | pubmed:author | pubmed-author:NimbergR RRR | lld:pubmed |
| pubmed-article:69489 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:69489 | pubmed:volume | 37 | lld:pubmed |
| pubmed-article:69489 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:69489 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:69489 | pubmed:pagination | 3022-5 | lld:pubmed |
| pubmed-article:69489 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:69489 | pubmed:meshHeading | pubmed-meshheading:69489-Hu... | lld:pubmed |
| pubmed-article:69489 | pubmed:meshHeading | pubmed-meshheading:69489-An... | lld:pubmed |
| pubmed-article:69489 | pubmed:meshHeading | pubmed-meshheading:69489-Mi... | lld:pubmed |
| pubmed-article:69489 | pubmed:meshHeading | pubmed-meshheading:69489-Ne... | lld:pubmed |
| pubmed-article:69489 | pubmed:meshHeading | pubmed-meshheading:69489-Pe... | lld:pubmed |
| pubmed-article:69489 | pubmed:meshHeading | pubmed-meshheading:69489-Fe... | lld:pubmed |
| pubmed-article:69489 | pubmed:meshHeading | pubmed-meshheading:69489-Al... | lld:pubmed |
| pubmed-article:69489 | pubmed:meshHeading | pubmed-meshheading:69489-Im... | lld:pubmed |
| pubmed-article:69489 | pubmed:meshHeading | pubmed-meshheading:69489-Mi... | lld:pubmed |
| pubmed-article:69489 | pubmed:meshHeading | pubmed-meshheading:69489-Im... | lld:pubmed |
| pubmed-article:69489 | pubmed:meshHeading | pubmed-meshheading:69489-Cy... | lld:pubmed |
| pubmed-article:69489 | pubmed:meshHeading | pubmed-meshheading:69489-An... | lld:pubmed |
| pubmed-article:69489 | pubmed:meshHeading | pubmed-meshheading:69489-He... | lld:pubmed |
| pubmed-article:69489 | pubmed:meshHeading | pubmed-meshheading:69489-T-... | lld:pubmed |
| pubmed-article:69489 | pubmed:year | 1977 | lld:pubmed |
| pubmed-article:69489 | pubmed:articleTitle | Suppression of tumor-specific cell-mediated cytotoxicity by immunoregulatory alpha-globulin and by immunoregulatory alpha-globulin-like peptides from cancer patients. | lld:pubmed |
| pubmed-article:69489 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:69489 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:69489 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:69489 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:69489 | lld:pubmed |
